Bioquell Share Discussion Threads

[temo82] 16/1/2014 22:47

any thoughts when the trading update will be released?

[bbluesky] 16/12/2013 21:24

Given how conservative this company is (cash rich!), I would read the directors' buying as a strong vote of confidence in the business. 20% top ups are quite chunky. Last sales by the way were 2 x cashing in options 19/3/10. In this RNS the Chairman Nigel Keen has made his biggest ever single purchase.

[temo82] 16/12/2013 08:03

apad - can't see an announcement for the trade you're pointing out! Where did you find that info?The only other trades I can see go back to 2011 and they're no where as big as the recent one.

[apad] 14/12/2013 17:13

M,
One of the directors buying had already sold at a higher price. Looks more like trading than taking advantage of a low price to me (not a clear distinction I know).
Not a clear signal in my view.
This ought to be a no-brainer, but I remain wary,
Thanks for the Glassdoor link.
apad

[mach100] 14/12/2013 14:59

www.glassdoor.com/.../Working-at-Bioquell-Group-EI_IE12389.11,25

Sure, you git! Sorry my memory is bad, it is glassdoor and not room.

[brummy_git] 14/12/2013 14:54

Mach100 - Please could you post the link to the glassroom site (re BQE employees)?

[mach100] 14/12/2013 12:21

Some large directors buys at 135p but the company is rather unloved. On glassroom's site four former employees from 4 reviews rated the company as terrible to work for among the lower echelons. I think given the buys there is upside from here to 150p, provided there is no general market reversal. Might be some progression when we get the FY results. I will stay just holding for now while I wait for the reaction to the end of tapering as if the whole market goes south we will easily see 121p again. I remember these were 96p before too but at least pay a nice divi.

[mach100] 16/11/2013 16:29

I have said before bluesky that I don't think the MRSA angle is going to be a winner. The NHS is in disarray and MRSA has been a contentious issue for a long time without Bioquell managing to capitalise. From memory I think BQE offered their product for free or cheap to a hospital (possibly in Stoke) and the offer wasn#t accepted. The defence contract could well be a game changer but the company needs to sort out its communications as to get hammered for vagueness is avoidable and unprofessional on behalf of the company. If it cuts the divi I am out.

[apad] 16/11/2013 07:16

Paul Scott:

"Bioquell (LON:BQE) has issued an IMS today, but it's all too vague. All investors need to know is how the year is progressing against market expectations. Everything else is just background noise. In this case, the only useful information I can ascertain from Bioquell's IMS is that orders & revenues are up against last year. They don't give any indication how much they are up, or how profits are looking. So all in all it's a largely useless statement from my point of view.
Their shares are down almost 6% to 138p, and that looks to be a forward PER of about 14, which looks about right. The dividend is reasonable, at about 2.5%."

illustrates the honest scribe's dilemma.
apad

[apad] 16/11/2013 07:10

bb
My position too.
Most companies are putting caveats in about Asia.
Storm in a teacup: (FLASH: Investec retains hold on Bioquell, target cut from 148p to 147p).
Having said that BQE don't have anything new to boast about - or they would have done so.
They are conservative, in a sense, but there is a large, and continuing, spend on the new product model and its international roll out.
There can't be blockbuster announcements resulting from what is happening at BQE, but success should lead to geometric growth.
I have increased since Spring 2010 and will be interested if there is any share price weakness next week, but I don't expect it.
apad

[bbluesky] 15/11/2013 21:21

Asia is minor: not even on their map x years ago. The ignorant will not be rewarded!

This company has always been very conservative( on AIM, cash rich!! omg). For the short termers, you may be right Mach, a defence deal will change things, but for the long termers, TRAC is continuing to go gangbusters and they are now looking international and the companies new products seem to be accepted+. They are addressing arguably one of the biggest issues in health care and if it was a specific cancer related drug price would be up in the stars, but as we read on a daily basis hospitals kill more patients through infection than cancer does. The hospital side can be improved through BQE it seems, though that is only one aspect of the biz!

One man's meat is another's poison on today's reaction!

[mach100] 15/11/2013 16:44

Hmmm can't see it having much downside though zip as it really has been hammered today for nothing more than vagueness about Asia. If that substantial Middle Eastern defence contract comes in this will recover no bother. It has also been paying dividends so I am happy to hold as I see little downside and a bounce on any news.

[zipstuck] 15/11/2013 13:43

Think this is veiled attmpt at saying that orders will slip into next year. Had expectations been met they would have said so. Will flat line until orders become clear IMO. Shame. Have sold.

[mach100] 15/11/2013 13:32

Shrewd move apad, can't see any justification for a such a large drop on mostly satisfactory updates. Even defense is doing well as the share is tanking.

[apad] 15/11/2013 10:15

Overdone?
Increased at 136.5.
apad

[pug151] 15/11/2013 09:08

Must be the asian question

[mach100] 15/11/2013 07:53

Trading is ahead of period to last October but the statement is a bit short of specific numbers. However all divisions except for the fluctuating asia seems to be performing well. I was considering selling up BQE when they hit 160p but on today's evidence I will be holding beyond that and may add on weakness. There is a hint of a significant revenue from the Middle East in Defense and I would say QUBE is going to be a significant earner. I am looking for a small rise to 149p on this.

[apad] 15/11/2013 07:23

In a word - steady.
Key to unlocking shareholder value is the throttling back of capital expenditure.
Only one job on offer.
No reason to increase holding.
I expect some weakness in share price
apad

[bbluesky] 15/11/2013 07:15

Interims out: "increasing", "increasing", "strong", "more" and major footholds established with new products. All systems go with the exception of Asia which is "fluctuating". An excellent read.

[bbluesky] 25/9/2013 16:58

Steady buying throughout the day a 5k a pop. So 9 x 5k, 45k. There has been a lot of activity lately, given that this can hibernate!

[woodcutter] 18/9/2013 09:46

i bought in a while ago mainly for the TRAC business more than the Health side but sold my entire holding (for a small profit) into the recent share price rise based on the financials at the H1 results.

Sales may have increased by by 10% on H1 comparison and the order book looks reasonable but o/heads excluding R&D increased by 19% on H1 comparison. Gross margin remains the same so that's good news. H1 Revenue was also less than H2 period last year.

If we consider the annualised savings at £1.2m and the £0.9m exceptional cost then reconfigure back to this H1 the o/heads excluding R&D would be reduced by roughly £1.5m (half the £1.2m + £0.9m)

So Revenue £21.2m
GPft £9.5m
op cost £7m
op profit £2.5m
pbt after interest deductions £2.3m
pat £1.84m roughly 20% tax rate for R&D allowance
eps 4.4p

forecast 8.4p so i figure valuation about right. PER is higher than recent historic values too. There maybe more in it but after the recent rise not sure, risk reward unbalanced so will consider buying again on any dips in share price

Woody

[bbluesky] 17/9/2013 22:05

For a hardly traded share decent volumes the last couple of days, stale vs new?, Q is what is the balance? For those that like medium, long term scenarios, worth researching imo.

[bbluesky] 09/9/2013 22:38

M100 If BQE does break through 161 I too will be excited and I think it will. Used to be NHS target market now global, but hopefully from a tax payers point of view NHS to follow. Good luck with SUMM

[mach100] 09/9/2013 20:09

Not holding out much hope myself on their product to beat MRSA which oddly was what attracted me to the company in the first place. It should have been a game changer but I guess that fact that bioquell hasn't got it established says buckets about the NHS and successive governments than the product. I remember this being 161p many moons ago. Would love to see it break through that resistance level. A nice share to have even if a bumpy ride at times.Off topic but anyone got a handle on summit corporation. Seems to be motoring but can't find any threads on it or reason for the rise.

[bbluesky] 09/9/2013 20:04

Personally, I don't think in the near term, as there is good traction in setting and checking regulatory standards for bio, which is an area TRAC have moved into. If it became a conflict then yes. The other aspect is that this is a very conservative company, they are cash rich, so don't need to service debt with a listing! Await the RNS tomorrow...